ARS Pharmaceuticals, Inc.
SPRY
$8.25
-$0.05-0.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.21% | -13.97% | -32.24% | -167.97% | 361.05% |
| Total Depreciation and Amortization | 6.65% | 40.14% | -0.36% | 865.52% | 38.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.13% | -21.12% | 81.72% | 22.73% | 54.05% |
| Change in Net Operating Assets | -597.48% | -1.71% | 89.90% | 2.43% | -471.41% |
| Cash from Operations | 7.57% | -18.83% | 2.82% | -197.00% | 390.34% |
| Capital Expenditure | 100.00% | -286.27% | 43.96% | 69.87% | -115.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 153.85% | -192.11% | 66.77% | 128.74% | -698.29% |
| Cash from Investing | 153.61% | -192.61% | 67.12% | 128.56% | -705.07% |
| Total Debt Issued | -101.53% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 271.61% | -82.24% | 272.00% | -52.71% | 125.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -53.52% | -- | -- | -- | -- |
| Cash from Financing | -98.87% | 3,609.49% | 272.00% | -98.98% | 10,328.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -327.52% | -31.34% | 206.60% | -198.15% | 268.20% |